Germany · Delayed Price · Currency is EUR IRLAB Therapeutics AB Statistics
Total Valuation
FRA:6IRA has a market cap or net worth of EUR 15.85 million. The enterprise value is 8.36 million.
| Market Cap | 15.85M |
| Enterprise Value | 8.36M |
Important Dates
The next estimated earnings date is Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 84.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +13.14% |
| Shares Change (QoQ) | +51.98% |
| Owned by Insiders (%) | 13.85% |
| Owned by Institutions (%) | 19.77% |
| Float | 66.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.05 |
| PB Ratio | 3.23 |
| P/TBV Ratio | 23.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.01 |
| EV / Sales | 1.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.30 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.83 |
Financial Efficiency
Return on equity (ROE) is -199.29% and return on invested capital (ROIC) is -49.63%.
| Return on Equity (ROE) | -199.29% |
| Return on Assets (ROA) | -27.35% |
| Return on Invested Capital (ROIC) | -49.63% |
| Return on Capital Employed (ROCE) | -89.89% |
| Revenue Per Employee | 249,638 |
| Profits Per Employee | -268,181 |
| Employee Count | 31 |
| Asset Turnover | 0.52 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:6IRA had revenue of EUR 7.74 million and -8.31 million in losses. Loss per share was -0.14.
| Revenue | 7.74M |
| Gross Profit | -2.77M |
| Operating Income | -6.55M |
| Pretax Income | -8.31M |
| Net Income | -8.31M |
| EBITDA | -6.48M |
| EBIT | -6.55M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 9.96 million in cash and 2.70 million in debt, with a net cash position of 7.27 million.
| Cash & Cash Equivalents | 9.96M |
| Total Debt | 2.70M |
| Net Cash | 7.27M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.90M |
| Book Value Per Share | 0.06 |
| Working Capital | 2.46M |
Cash Flow
| Operating Cash Flow | -4.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -35.80%, with operating and profit margins of -84.62% and -107.43%.
| Gross Margin | -35.80% |
| Operating Margin | -84.62% |
| Pretax Margin | -107.43% |
| Profit Margin | -107.43% |
| EBITDA Margin | -83.79% |
| EBIT Margin | -84.62% |
| FCF Margin | n/a |
Dividends & Yields
FRA:6IRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.14% |
| Shareholder Yield | -13.14% |
| Earnings Yield | -52.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:6IRA has an Altman Z-Score of -4.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.48 |
| Piotroski F-Score | 4 |